At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Mar 12, 2026 at 07:00 ET
Relmada Therapeutics announced plans to host a conference call on March 19, 2026, to discuss its Q4 and full-year 2025 financial results. The press release contains no actual financial data, guidance, or material business updates, serving only as a notification of the upcoming earnings event.
- Relmada Therapeutics will host a conference call on March 19, 2026, at 4:30 PM ET to discuss Q4 and full-year 2025 financial results.
- No financial results, guidance, or material operational updates were disclosed in the press release.
- The company remains in clinical-stage development with lead candidates NDV-01 and sepranolone in mid-stage trials.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access